In Vivo Kinetic Biomarkers of Hepatic Toxicity

Information

  • Research Project
  • 6942609
  • ApplicationId
    6942609
  • Core Project Number
    R43CA110965
  • Full Project Number
    5R43CA110965-02
  • Serial Number
    110965
  • FOA Number
    PA-02-75
  • Sub Project Id
  • Project Start Date
    9/1/2004 - 20 years ago
  • Project End Date
    8/31/2007 - 17 years ago
  • Program Officer Name
    RAPAKA, RAO
  • Budget Start Date
    9/1/2005 - 19 years ago
  • Budget End Date
    8/31/2007 - 17 years ago
  • Fiscal Year
    2005
  • Support Year
    2
  • Suffix
  • Award Notice Date
    8/8/2005 - 19 years ago
Organizations

In Vivo Kinetic Biomarkers of Hepatic Toxicity

DESCRIPTION (provided by applicant): A flood of drug candidates increases the need for novel assays to measure liver toxicity. We have developed methods for quantifying multiple metabolic fluxes in vivo using 2H2O labeling. Here we propose to validate this approach as a toxicity screen. We will test 14 hepatotoxins with diverse mechanisms of action for their ability to alter liver cell turnover (hepatocytes, endothelial cells, total liver cells), mitochondrial biogenesis, and collagen synthesis as markers of liver damage and homeostasis. We will correlate these measurements with changes in static markers of cell division; morphology of sinusoidal endothelial cells; mitochondrial cytochrome c; and collagen deposition, respectively. We hypothesize that toxic concentrations of drugs known to affect the latter phenotypes will strongly modulate fluxes in the underlying metabolic pathways. We will compare static markers and 2H labeling for their ability to detect drug-induced subclinical changes at limiting doses/exposure times and to reveal novel toxic activities. Finally, we will screen for gene expression patterns that predict end organ damage as detected by our test. This work will provide a solid foundation for regulatory approval of our toxicity screen, for extension of our work to other end organs, and for use in humans.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    250000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:250000\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    KINEMED, INC.
  • Organization Department
  • Organization DUNS
    067568266
  • Organization City
    EMERYVILLE
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94608
  • Organization District
    UNITED STATES